• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Pharmacogenetic Testing Used—and Useful—in Clinical Practice?

Is Pharmacogenetic Testing Used—and Useful—in Clinical Practice?

February 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
GENETICS

Short Description:
Is Pharmacogenetic Testing Used—and Useful—in Clinical Practice?

Background:

For years, we have read articles about the promise of pharmacogenetic testing to help us choose and monitor medication treatment. But relatively few psychiatrists actually use the cytochrome P450 (CYP450) genotyping tests that are available, and the last time we wrote about the topic (TCPR, August 2007), our expert opined that they added little of value to clinical decision making.

Basically, the currently available tests can tell you whether a patient will metabolize certain drugs “rapidly” or “slowly.” Presumably, one might use this data to increase or to decrease the dose, or to switch to a different drug altogether.

But how useful has genotyping been in real psychiatric settings? In a retrospective study, a Danish group reviewed the charts of all inpatients who received CYP450 testing upon admission to a mental health center between 2003 and 2009. Of 967 patients who had received the testing, 117 (12%) were found to be either “ultrarapid” or “poor” metabolizer for CYP2D6 or CYP3C19.

Most of these (101, or 86%) were actually treated with drugs metabolized by the enzyme(s) for which they had deviant results. However, this fact was noted in the chart in only about half (53) of these cases, and only 28 received “further action,” which was usually documented as “clinical observation” or “monitor drug concentration.”

The researchers observed that CYP450 testing was poorly adopted in daily clinical practice. Psychiatrists rarely actually used the test results, due to various factors: they were ordered by a different physician than the one responsible for long-term management; the results sometimes arrived after medication decisions had been made; they may have been hidden in the electronic medical record; or there were at times combined with other test results and often ignored.

The researchers didn’t elaborate on clinical outcomes, so we don’t know whether the CYP-tested patients fared better, nor whether patients receiving CYP450-dependent drugs experienced any adverse effects. The purpose of the study was strictly to describe how testing affected medical decision-making (Jürgens G et al, Acta Psychiatr Scand 2011;1–10:online ahead of print).

TCPR's Take:
The value of CYP450 genotyping in psychiatry is still in question. Even where testing is widely performed, psychiatrists rarely use the results and appear to make medication decisions the old fashioned ways—by assessing response or getting blood levels of drugs. This study was conducted on inpatients; it’s arguable that in outpatient practice the physician who ordered the test would almost surely be the same one getting the results. It is unclear from this study whether this implies that the testing has little utility or that psychiatrists need to learn how to better use the results—or some combination of the two.
General Psychiatry
KEYWORDS genetics_and_psychiatry research_updates
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2012
    SUBSCRIBE NOW
    Table Of Contents
    Are Clinical Scales Useful for Adult ADHD?
    A Boatload of New Data on Stimulants and Cardiac Events
    Diagnosis and Treatment of ADHD in Adults
    Is Pharmacogenetic Testing Used—and Useful—in Clinical Practice?
    How Risky is Pregnancy for Women with a History of Mood Disorders?
    FDA Publishes Article Critical of Vilazodone Data
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.